Although TP53 mutations has been reported to be associated with inferior response to EGFR‐TKIs and poor outcome in EGFR‐mutated NSCLC patients, the association between TP53 mutations and the effect of crizotinib treatment in ALK‐rearranged NSCLC patients was still uncertain. This evidence concerns the gene EGFR and non-small cell lung carcinoma.